Paying users zone. Data is covered by 
.
Get to Allergan PLC for $15.99, or
get to whole website for at least 3 months from $49.99.
Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Difficulty: Beginner
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Allergan PLC, historical price multiples (quarterly data)
Based on: 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05), 10-K (filing date: 2014-02-25), 10-Q (filing date: 2013-10-31), 10-Q (filing date: 2013-07-30), 10-Q (filing date: 2013-05-07).
| Ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Allergan PLC's P/S ratio increased from Q1 2018 to Q2 2018 but then slightly declined from Q2 2018 to Q3 2018 not reaching Q1 2018 level. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return. | Allergan PLC's P/BV ratio increased from Q1 2018 to Q2 2018 but then slightly declined from Q2 2018 to Q3 2018 not reaching Q1 2018 level. |
Price to Earnings (P/E)
Allergan PLC, historical P/E calculation (quarterly data)
Based on: 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05), 10-K (filing date: 2014-02-25), 10-Q (filing date: 2013-10-31), 10-Q (filing date: 2013-07-30), 10-Q (filing date: 2013-05-07).
1 Data adjusted for splits and stock dividends.
2 Close price on the filing date of Allergan PLC's Quarterly or Annual Report.
Q3 2018 Calculations
3 EPS
= (Net income (loss) attributable to ordinary shareholdersQ3 2018
+ Net income (loss) attributable to ordinary shareholdersQ2 2018
+ Net income (loss) attributable to ordinary shareholdersQ1 2018
+ Net income (loss) attributable to ordinary shareholdersQ4 2017)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
4 P/E ratio = Share price ÷ EPS
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. |
Price to Operating Profit (P/OP)
Allergan PLC, historical P/OP calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selected Financial Data (USD $) | ||||||||||||||||||||||||
| Operating income (loss) (in thousands) | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating profit per share3 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price1, 2 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P/OP ratio4 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05), 10-K (filing date: 2014-02-25), 10-Q (filing date: 2013-10-31), 10-Q (filing date: 2013-07-30), 10-Q (filing date: 2013-05-07).
1 Data adjusted for splits and stock dividends.
2 Close price on the filing date of Allergan PLC's Quarterly or Annual Report.
Q3 2018 Calculations
3 Operating profit per share
= (Operating income (loss)Q3 2018
+ Operating income (loss)Q2 2018
+ Operating income (loss)Q1 2018
+ Operating income (loss)Q4 2017)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
4 P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. |
Price to Sales (P/S)
Allergan PLC, historical P/S calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selected Financial Data (USD $) | ||||||||||||||||||||||||
| Net revenues (in thousands) | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales per share3 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price1, 2 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P/S ratio4 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05), 10-K (filing date: 2014-02-25), 10-Q (filing date: 2013-10-31), 10-Q (filing date: 2013-07-30), 10-Q (filing date: 2013-05-07).
1 Data adjusted for splits and stock dividends.
2 Close price on the filing date of Allergan PLC's Quarterly or Annual Report.
Q3 2018 Calculations
3 Sales per share
= (Net revenuesQ3 2018
+ Net revenuesQ2 2018
+ Net revenuesQ1 2018
+ Net revenuesQ4 2017)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
4 P/S ratio = Share price ÷ Sales per share
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Allergan PLC's P/S ratio increased from Q1 2018 to Q2 2018 but then slightly declined from Q2 2018 to Q3 2018 not reaching Q1 2018 level. |
Price to Book Value (P/BV)
Allergan PLC, historical P/BV calculation (quarterly data)
| Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Selected Financial Data (USD $) | ||||||||||||||||||||||||
| Shareholders' equity (in thousands) | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Book value per share (BVPS)3 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price1, 2 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| P/BV ratio4 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Based on: 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-03), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-09), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-24), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-26), 10-Q (filing date: 2015-11-06), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-11), 10-K (filing date: 2015-02-18), 10-Q (filing date: 2014-11-05), 10-Q (filing date: 2014-08-05), 10-Q (filing date: 2014-05-05), 10-K (filing date: 2014-02-25), 10-Q (filing date: 2013-10-31), 10-Q (filing date: 2013-07-30), 10-Q (filing date: 2013-05-07).
1 Data adjusted for splits and stock dividends.
2 Close price on the filing date of Allergan PLC's Quarterly or Annual Report.
Q3 2018 Calculations
3 BVPS = Shareholders' equity ÷ No. shares of common stock outstanding
= ÷ =
4 P/BV ratio = Share price ÷ BVPS
= ÷ =
| Ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return. | Allergan PLC's P/BV ratio increased from Q1 2018 to Q2 2018 but then slightly declined from Q2 2018 to Q3 2018 not reaching Q1 2018 level. |
